In WHO grade IV GBM, IDH mutation has been repeatedly shown to be predictive of improved response to temozolomide treatment and radiotherapy in secondary GBM malignancies that have transformed from lower grade gliomas [39,40]. This evidence concerns the gene IDH2 and central nervous system cancer.